ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding
- 1 April 2016
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 111 (4), 459-474
- https://doi.org/10.1038/ajg.2016.41
Abstract
This guideline provides recommendations for the management of patients with acute overt lower gastrointestinal bleeding. Hemodynamic status should be initially assessed with intravascular volume resuscitation started as needed. Risk stratification based on clinical parameters should be performed to help distinguish patients at high- and low-risk of adverse outcomes. Hematochezia associated with hemodynamic instability may be indicative of an upper gastrointestinal (GI) bleeding source and thus warrants an upper endoscopy. In the majority of patients, colonoscopy should be the initial diagnostic procedure and should be performed within 24 h of patient presentation after adequate colon preparation. Endoscopic hemostasis therapy should be provided to patients with high-risk endoscopic stigmata of bleeding including active bleeding, non-bleeding visible vessel, or adherent clot. The endoscopic hemostasis modality used (mechanical, thermal, injection, or combination) is most often guided by the etiology of bleeding, access to the bleeding site, and endoscopist experience with the various hemostasis modalities. Repeat colonoscopy, with endoscopic hemostasis performed if indicated, should be considered for patients with evidence of recurrent bleeding. Radiographic interventions (tagged red blood cell scintigraphy, computed tomographic angiography, and angiography) should be considered in high-risk patients with ongoing bleeding who do not respond adequately to resuscitation and who are unlikely to tolerate bowel preparation and colonoscopy. Strategies to prevent recurrent bleeding should be considered. Nonsteroidal anti-inflammatory drug use should be avoided in patients with a history of acute lower GI bleeding, particularly if secondary to diverticulosis or angioectasia. Patients with established cardiovascular disease who require aspirin (secondary prophylaxis) should generally resume aspirin as soon as possible after bleeding ceases and at least within 7 days. The exact timing depends on the severity of bleeding, perceived adequacy of hemostasis, and the risk of a thromboembolic event. Surgery for the prevention of recurrent lower gastrointestinal bleeding should be individualized, and the source of bleeding should be carefully localized before resection.Keywords
This publication has 131 references indexed in Scilit:
- Clinical Application and Outcomes of Over the Scope Clip Device: Initial US Experience in HumansDiagnostic and Therapeutic Endoscopy, 2013
- The role of colonoscopy in evaluating hematochezia: a population-based study in a large consortium of endoscopy practicesGastrointestinal Endoscopy, 2013
- Bleeding Risk after Invasive Procedures in Aspirin/NSAID Users: Polypectomy Study in VeteransThe American Journal of Medicine, 2012
- Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panelCritical Care, 2011
- Gastroesophageal reflux disease: Important considerations for the older patientsWorld Journal of Gastrointestinal Endoscopy, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Obesity Increases the Risks of Diverticulitis and Diverticular BleedingGastroenterology, 2009
- Risk Factors for Mortality in Lower Intestinal BleedingClinical Gastroenterology and Hepatology, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Usefulness and validity of diagnostic nasogastric aspiration in patients without hematemesisAnnals of Emergency Medicine, 2004